Tumor Necrosis Factor Receptor Superfamily Member 1A-Pipeline Product 2019

Albany, US, 2019-Oct-01 — /EPR Network/ —Market Research Hub (MRH) has recently uploaded a new study titled “Tumor Necrosis Factor Receptor Superfamily Member 1A-Pipeline Review, H2 2019” to its broad online storehouse. The global Tumor Necrosis Factor Receptor Superfamily Member 1A conveniently covers prime factors motivating development and steering industry trends and demand scenarios. Readers can easily quantify market opportunities with the availability of information such as market sizing and market forecasting, thereby being able to analyze the prevailing status across the global Tumor Necrosis Factor Receptor Superfamily Member 1A.

Get Sample Copy@ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2519488

Tumor Necrosis Factor Receptor Superfamily Member 1A – Pipeline Review, H2 2019

Summary

According to the recently published report ‘Tumor Necrosis Factor Receptor Superfamily Member 1A – Pipeline Review, H2 2019’; Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) pipeline Target constitutes close to 14 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes.

Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) – Tumor necrosis factor receptor 1 (TNFR1) is a ubiquitous membrane receptor that binds tumor necrosis factor-alpha (TNFalpha). This receptor activates NF-kappaB, mediate apoptosis and function as a regulator of inflammation. Mutations in this receptor were found to be associated with tumor necrosis factor associated periodic syndrome (TRAPS).

The report ‘Tumor Necrosis Factor Receptor Superfamily Member 1A – Pipeline Review, H2 2019’ outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 1, 2, 4 and 3 respectively.

Similarly, the universities portfolio in Phase I stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Dermatology, Central Nervous System, Gastrointestinal, Immunology, Undisclosed, Infectious Disease and Ophthalmology which include indications Atopic Dermatitis (Atopic Eczema), Multiple Sclerosis, Non-Alcoholic Steatohepatitis (NASH), Soft Tissue Sarcoma, Unspecified, Actinic (Solar) Keratosis, Alzheimer’s Disease, Bile Duct Cancer (Cholangiocarcinoma), Breast Cancer, Colon Cancer, Gastrointestinal Tract Cancer, Genital Warts (Condylomata Acuminata), Glioma, Inflammation, Intermediate Uveitis, Kidney Cancer (Renal Cell Cancer), Liver Fibrosis, Melanoma, Metastatic Melanoma, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Endocrine Tumor, Posterior Uveitis, Prostate Cancer, Psoriasis, Retinitis Pigmentosa (Retinitis), Rheumatoid Arthritis, Solid Tumor, Thyroid Cancer and Warts.

Scope

– The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A)
– The report reviews Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) targeted therapeutics and enlists all their major and minor projects
– The report assesses Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) targeted therapeutics

Request TOC of the Report @ https://www.marketresearchhub.com/report/tumor-necrosis-factor-receptor-superfamily-member-1a-pipeline-review-h2-2019-report.html

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) – Overview
Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) – Companies Involved in Therapeutics Development
CytImmune Sciences Inc
Eyevensys SAS
G&E Corp
Hillstream BioPharma Inc
Inflamalps SA
Inmune Bio Inc
Philogen SpA
Promethera Biosciences SA
Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) – Drug Profiles
Atrosab – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Atrosab (improved formulation) – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Atrosimab – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CYT-21625 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
daromun – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Antagonize TNFRSF1A for Inflammation – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EYS-606 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fibromun – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to Antagonize TNFRSF1A for Unspecified Indication – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HSB-114 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INB-03 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptides to Antagonize TNFR-1 for Atopic Dermatitis – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize TNFR-1 for Atopic Dermatitis – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRT-100 – Drug Profile
Product Description
Mechanism Of Action

Continued…………#@

Enquire about This Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2519488

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports of different sector like Pharmaceuticals market research   and analysis. MRH’s expansive collection of industry reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Us

90 State Street,

Albany, NY 12207,

United States

Toll Free: 800-998-4852 (US-Canada)

Email: press@marketresearchhub.com

Website: http://www.marketresearchhub.com/

Read Industry News at: https://www.industrynewsanalysis.com/

 

Matched content

Editor’s pick

Express Press Release Distribution